Skip Navigation



Carcinogenesis Advance Access published online on May 21, 2008
Carcinogenesis, doi:10.1093/carcin/bgn123
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
29/7/1421    most recent
bgn123v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Guillen-Ahlers, H.
Right arrow Articles by Ploplis, V. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guillen-Ahlers, H.
Right arrow Articles by Ploplis, V. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice

Hector Guillen-Ahlers1,2, Steven Buechler4, Mark Suckow3,5, Francis J. Castellino1,2,3 and Victoria A. Ploplis1,2,3

1 W. M. Keck Center for Transgene Research
2 Department of Chemistry and Biochemistry
3 Notre Dame Cancer Institute
4 Department of Mathematics
5 Freimann Life Science Center, University of Notre Dame, Notre Dame, IN 46556

Corresponding author: Victoria A. Ploplis, Ph.D., W. M. Keck Center for Transgene Research, 230 Raclin-Carmichael Hall, University of Notre Dame, Notre Dame, Indiana 46556, Phone:(574) 631-4017, Fax:(574) 631-4414, e-mail:vploplis{at}nd.edu

Non-steroidal anti-inflammatory drugs (NSAIDs) have shown potential as chemopreventive agents against cancer formation, especially colorectal cancers. However, the mechanisms by which these drugs act are not fully understood. In this study, ApcMin/+ mice, a genetic model of human familial adenomatous polyposis (FAP), were treated with sulindac, and these mice demonstrated tumor reduction of over 80%, consistent with previous reports. Gene microarray analyses of RNA from adenoma-derived dysplastic epithelial cells revealed that collagen genes, viz., Col1a2, Col5a2, Col6a2, and Col6a3, were upregulated, and matrilysin (Mmp7) was downregulated, in sulindac-treated mice. RT-PCR validated gene expression of the Col6a2 subunit of collagen VI and of Mmp7. Confocal microscopy and immunofluorescence showed that within the tumors of nontreated mice, collagen VI was present in low amounts, but was enhanced within the tumors of sulindac-treated mice. Collagens I and V demonstrated similar patterns, but were not as prominent as collagen VI. MMP7 was found in ‘hot spot’ areas within the tumors of ApcMin/+ mice treated with the vehicle, but was greatly diminished in those mice treated with sulindac. Studies with ApcMin/+/Mmp7-/- double-deficient mice demonstrated the reciprocal relationships of Mmp7 expression and the levels of these three collagens in vivo. The results of this study demonstrated that sulindac was effective in increasing the expression of different collagens, and decreasing the expression of Mmp7, effects that may contribute to altered tumor burden in cancer patients undergoing NSAIDS treatments.

Key Words: sulindac • intestinal adenomas • adenomatous polyposis coli gene • collagen • matrilysin

Received February 19, 2008; revised May 6, 2008; accepted May 15, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.